Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M28,554Revenue (TTM) $M2,705Net Margin (%)5.4Altman Z-Score4.2
Enterprise Value $M30,947EPS (TTM) $0.7Operating Margin %22.1Piotroski F-Score4
P/E(ttm)177Beneish M-Score-2.1Pre-tax Margin (%)19.8Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %--Quick Ratio3.0Cash flow > EarningsY
Price/Sales10.35-y EBITDA Growth Rate %35.4Current Ratio3.5Lower Leverage y-yN
Price/Free Cash Flow52.5y-y EBITDA Growth Rate %-3.3ROA % (ttm)1.3Higher Current Ratio y-yN
Dividend Yield %--PEG4.9ROE % (ttm)2.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M224ROIC % (ttm)1.9Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNJohn Paulson 2016-03-31 Buy 0.17%$127.91 - $190.75
($147.61)
$ 127.46-14%New holding157,200
ALXNJoel Greenblatt 2016-03-31 Buy 0.02%$127.91 - $190.75
($147.61)
$ 127.46-14%New holding10,684
ALXNRon Baron 2016-03-31 Reduce$127.91 - $190.75
($147.61)
$ 127.46-14%Reduce -8.54%55,950
ALXNDodge & Cox 2016-03-31 Buy $127.91 - $190.75
($147.61)
$ 127.46-14%New holding1,820
ALXNRon Baron 2015-12-31 Add0.02%$152.66 - $191.88
($175.28)
$ 127.46-27%Add 87.52%61,177
ALXNDavid Swensen 2015-09-30 Sold Out -16.37%$145.6 - $207.84
($182.41)
$ 127.46-30%Sold Out0
ALXNRon Baron 2015-09-30 Reduce-0.03%$145.6 - $207.84
($182.41)
$ 127.46-30%Reduce -53.24%32,624
ALXNMario Gabelli 2015-09-30 Sold Out $145.6 - $207.84
($182.41)
$ 127.46-30%Sold Out0
ALXNDavid Swensen 2015-06-30 Buy 16.37%$155.01 - $190.92
($172.58)
$ 127.46-26%New holding319,273
ALXNJoel Greenblatt 2015-06-30 Sold Out -0.03%$155.01 - $190.92
($172.58)
$ 127.46-26%Sold Out0
ALXNRon Baron 2015-06-30 Add0.02%$155.01 - $190.92
($172.58)
$ 127.46-26%Add 69.48%69,764
ALXNMario Gabelli 2015-06-30 Buy $155.01 - $190.92
($172.58)
$ 127.46-26%New holding1,415
ALXNJoel Greenblatt 2015-03-31 Reduce-0.09%$171.42 - $189.07
($181.01)
$ 127.46-30%Reduce -72.94%23,261
ALXNRon Baron 2015-03-31 Add0.02%$171.42 - $189.07
($181.01)
$ 127.46-30%Add 124.13%41,163
ALXNJoel Greenblatt 2014-12-31 Add0.13%$159.46 - $200.79
($185.68)
$ 127.46-31%Add 4665.74%85,974
ALXNRon Baron 2014-12-31 Add$159.46 - $200.79
($185.68)
$ 127.46-31%Add 41.92%18,366
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 127.46-22%Reduce -89.45%1,804
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 127.46-22%Add 27.56%12,941
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 127.46-19%Add 240.11%17,094
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 127.46-19%New holding5,026
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these investors:


News about ALXN:

Articles On GuruFocus.com
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 06 2016 
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 
Alexion Pharmaceuticals Loses Position in Swensen's Portfolio Dec 03 2015 
Jim Simons' Largest Adds of the 3rd Quarter Nov 13 2015 

More From Other Websites
Is Vertex Pharmaceuticals Exposed to Drug Pricing Risks? Jul 22 2016
How Alexion Plans to Fuel Strensiq Sales Jul 22 2016
How Can Alexion Stay ahead of the Competition with Soliris? Jul 22 2016
Wall Street Looks for Vertex Pharmaceuticals to Break Even in 2Q16 Jul 21 2016
Analysts Gauge Alexion Pharmaceuticals’ Return Potential Jul 21 2016
Will Alexion Pharmaceuticals’ 2Q16 Earnings Surprise? Jul 21 2016
Biotech: Steak, But No Sizzle Jul 15 2016
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive... Jul 14 2016
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive... Jul 14 2016
Amazon Target Primed; Top Banks Initiated Ahead Of Earnings Jul 13 2016
Alexion Pharmaceuticals (ALXN) Stock Gets ‘Outperform’ Rating at RBC Capital Jul 13 2016
16 Recently Upgraded Stocks (APD,ALXN,ADP,BHI) Jul 13 2016
Biotech: 'We Would Not Be Surprised to See Volatility Continue' Jul 13 2016
[$$] Three Biotech Picks With Pipeline Upside Jul 13 2016
Coverage initiated on Alexion Pharma by RBC Capital Mkts Jul 13 2016
Stocks in record territory Jul 12 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)